Present initial data from RP2 expansion patients
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Jan 2022
- Due
- 31 Dec 2022
- Delivered
- December 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The company expects to present initial data from the expansion patients in late 2022.”
What we found
Evidence strength A What the grades mean
The company reported initial data from its RP2 expansion trial in uveal melanoma patients in December 2022, fulfilling the commitment to present initial data by late 2022.
-
A Replimune Group, Inc. 10-Q filed 2023-02-09
“In December 2022, we reported that of 14 patients with uveal melanoma for which sufficient follow-up was available for assessment, 4 patients had achieved a response.” ✓ confirmed on the page
Market reaction: the shares moved -11.9% against the S&P 500 over the three sessions around the disclosure (8 Feb 2023 to 13 Feb 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- RP2 expansion patient initial data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-REPL-002653 · Corrections policy